News

PRINCETON, N.J. , April 21, 2023 /PRNewswire/ — Oblato, Inc. (the Company), a subsidiary company of HLB Therapeutics in Korea, has announced today the first enrollment for recurrent high-grade glioma patients in a Phase 1 clinical trial in the USA wi

PRINCETON, N.J. , Oct. 25, 2022 /PRNewswire/ — Oblato, Inc. (the Company) a subsidiary company of HLB Therapeutics in Korea, announced today that the enrollment of recurrent glioblastoma multiforme (GBM) patients for a Phase 2 clinical trial with its

PRINCETON, N.J. , July 19, 2021 /PRNewswire/ — Oblato, Inc. (the Company) announced today that it has received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-gra

PRINCETON, N.J. , March 3, 2021 /PRNewswire/ — Oblato, Inc. (the Company), a wholly owned U.S. subsidiary of the Korean biotech company GtreeBNT Co., Ltd., announces that the FDA granted Fast Track Designation of OKN-007, the proprietary drug for Dif

The day before Thanksgiving in 2015, Mike Schuster’s life changed in an instant. Teresa and Mike Schuster Schuster, then 50, blacked out when he suffered a seizure while working at his desk at a roofing company in Newcastle. The next thing he remembe

The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at th

PRINCETON, N.J. , Dec. 10, 2020 /PRNewswire/ — Oblato, Inc. (the Company), a wholly owned U.S. subsidiary of the Korean biotech company GtreeBNT Co., Ltd., announced it had official discussions with the FDA on a detailed plan for a phase 1/2 clinical